ClearFlow: Active Clearance Technology
Support
  • Blog
  • About
  • Press
  • FAQ
  • Resources
  • Education
  • Sales
  • Cost Calculator
  • Contact
  • Blog
  • About
  • Press
  • FAQ
  • Resources
  • Education
  • Sales
  • Cost Calculator
  • Contact
  • Support

ClearFlow: Active Clearance Technology

  • ChallengeRetained Blood Syndrome
  • SolutionPleuraFlow® ACT
  • MissionA New Standard

Year: 2010

Medical Device Start Up Clear Catheter Systems Raises $1.2 Million

by James Herlofsky

Financing was led by the Oregon Angel Fund (OAF), joined by additional Oregon based angel investors, and will support the clinical launch of the companyʼs lead product.

Read More

Clear Catheter Systems Announces CE Mark Approval

by James Herlofsky

and European Launch of the PleuraFlow Active Tube Clearance System

Read More

Clear Catheter Systems Announces Publication of Pre-Clinical Data

by James Herlofsky

Demonstrating Improved Drainage with the PleuraFlow Active Tube Clearance System

Read More

2010 Design Distinction Award

by James Herlofsky

In 2010, PleuraFlow® was awarded an international industrial design distinction award from I.D. Magazine.

Read More

Filter Posts

Recent Posts

  • Modernizing Your ICU Chest Tube Patency Protocol?
  • COVID-19 Pandemic – Message from our CEO
  • With Retained Blood, Bleeding Begets More Bleeding after Cardiac Surgery
  • Level 1A Evidence that Reducing Retained Blood Prevents POAF and Effusions After Cardiac Surgery
  • Preparing to Implement an ERAS Cardiac Surgery Value Quality Care Initiative

Archives

  • 2021
  • 2020
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008

ClearFlow: Active Clearance Technology

  • ChallengeRetained Blood Syndrome
  • SolutionPleuraFlow® ACT
  • MissionA New Standard
  • Blog
  • About
  • Press
  • FAQ
  • Resources
  • Education
  • Sales
  • Cost Calculator
  • Contact
Clinical References| Terms of Use| PleuraFlow ACT System Indications of Use|

PleuraFlow® ACT® is not indicated as a therapeutic device.

ClearFlow’s PleuraFlow® Active Clearance Technology® and many of its features are protected by a comprehensive family of both US and foreign patents and patent applications in major markets throughout the world, including Canada, Australia and the European Community. In the United States, PleuraFlow® products are protected by US Patent Nos. 7,854,728, 7,951,243, 8,246,752, 8,048,233, 8,388,759, 8,702,662 and 8,951,355. The PleuraFlow® product is the first device of its kind to effectively and reproducibly clear obstructing material from chest tubes without compromising the sterile field, and thus patient recovery. It is the only FDA 510(k) cleared device of its kind for this indication. ClearFlow’s patent portfolio has been tailored not only to protect this product, but also to provide protection around this new market segment thus presenting a barrier to entry for competing products.

Website by Bloom Creative